THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF PRIMARY ITP: EXPERIENCE OF APPLICATION IN CLINICAL PRACTICE ONE MEDICAL CENTER
(Abstract release date: 05/19/16)
EHA Library. Zotova I. 06/09/16; 134991; PB2091
Dr. Irina Zotova
Contributions
Contributions
Abstract
Abstract: PB2091
Type: Publication Only
Background
Therapy of thrombopoietin receptor agonists( aTPO-r) is a new approach to the treatment of patients with resistant primary ITP.Data on the effectiveness and safety of aTPO-r outside of controlled clinical trials is limited.
Aims
To study the efficacy and safety of prolonged use of aTPO-r in routine clinical practice in patients with chronic ITP in case of loss or inadequate response to at least one line of therapy. To evaluate the possibility of achieving a sustained response after the cessation of the aTPO-r therapy.
Methods
A retrospective analysis of aTPO-r threatment results in chronic ITP patients in the outpatient department in the period from 2010 to 2015.Romiplostim therapy received 45 patients(group 1) and eltrombopag therapy-15 patients(group 2).Efficacy was evaluated by levels of platelet response and the percentage of patients who managed to cancel or reduce the dose of drugs for concomitant ITP therapy.The main indicators of safety were incidence of adverse events,including thrombotic complications,bleeding and abnormalities in laboratory parameters.
Results
Twenty-one patients (47%) from 1 group and four (28%) from group 2 received two or more lines ITP therapy, nine of them underwent splenectomy .Platelet response was achieved in 88 % patients treated with romiplostim and in 93 % eltrombopag. During aTPO-r therapy the majority of patients (92 % from group 1 and 100% group 2) were able to completely cancel the previous long-term steroid therapy. Resistant to aTPO-r therapy were 8 patients-5(11%) from romiplostim group and 1(7%) eltrombopag group),three of them were splenectomised in future. The most frequent adverse events in romiplostim group were headache,arthralgia and dermatitis. This events were minimal and not require change in therapy.In eltrombopag group noted shot-term hepatotoxicity with the need for correction or therapy(dose reduction or treatment interruption)without additional hepatotropic therapy. Cancel aTpo-r therapy was required in connection with the development of thrombotic complications: 4% patients romiplostim group and 6% eltrombopag. Five patients (4 from the romiplostim group and 1 from eltrombopag) maintained a stable remission after discontinuation of aTPO-r therapy without any treatment.
Conclusion
Presented results confirm high efficiency,favorable safety profile aTPO-r,importance of this drugs in the modern ITP therapy algorithms,which was reflected in the inclusion of aTPO-r in national treatment standarts of ITP therapy.
Session topic: E-poster
Type: Publication Only
Background
Therapy of thrombopoietin receptor agonists( aTPO-r) is a new approach to the treatment of patients with resistant primary ITP.Data on the effectiveness and safety of aTPO-r outside of controlled clinical trials is limited.
Aims
To study the efficacy and safety of prolonged use of aTPO-r in routine clinical practice in patients with chronic ITP in case of loss or inadequate response to at least one line of therapy. To evaluate the possibility of achieving a sustained response after the cessation of the aTPO-r therapy.
Methods
A retrospective analysis of aTPO-r threatment results in chronic ITP patients in the outpatient department in the period from 2010 to 2015.Romiplostim therapy received 45 patients(group 1) and eltrombopag therapy-15 patients(group 2).Efficacy was evaluated by levels of platelet response and the percentage of patients who managed to cancel or reduce the dose of drugs for concomitant ITP therapy.The main indicators of safety were incidence of adverse events,including thrombotic complications,bleeding and abnormalities in laboratory parameters.
Results
Twenty-one patients (47%) from 1 group and four (28%) from group 2 received two or more lines ITP therapy, nine of them underwent splenectomy .Platelet response was achieved in 88 % patients treated with romiplostim and in 93 % eltrombopag. During aTPO-r therapy the majority of patients (92 % from group 1 and 100% group 2) were able to completely cancel the previous long-term steroid therapy. Resistant to aTPO-r therapy were 8 patients-5(11%) from romiplostim group and 1(7%) eltrombopag group),three of them were splenectomised in future. The most frequent adverse events in romiplostim group were headache,arthralgia and dermatitis. This events were minimal and not require change in therapy.In eltrombopag group noted shot-term hepatotoxicity with the need for correction or therapy(dose reduction or treatment interruption)without additional hepatotropic therapy. Cancel aTpo-r therapy was required in connection with the development of thrombotic complications: 4% patients romiplostim group and 6% eltrombopag. Five patients (4 from the romiplostim group and 1 from eltrombopag) maintained a stable remission after discontinuation of aTPO-r therapy without any treatment.
Conclusion
Presented results confirm high efficiency,favorable safety profile aTPO-r,importance of this drugs in the modern ITP therapy algorithms,which was reflected in the inclusion of aTPO-r in national treatment standarts of ITP therapy.
Session topic: E-poster
Abstract: PB2091
Type: Publication Only
Background
Therapy of thrombopoietin receptor agonists( aTPO-r) is a new approach to the treatment of patients with resistant primary ITP.Data on the effectiveness and safety of aTPO-r outside of controlled clinical trials is limited.
Aims
To study the efficacy and safety of prolonged use of aTPO-r in routine clinical practice in patients with chronic ITP in case of loss or inadequate response to at least one line of therapy. To evaluate the possibility of achieving a sustained response after the cessation of the aTPO-r therapy.
Methods
A retrospective analysis of aTPO-r threatment results in chronic ITP patients in the outpatient department in the period from 2010 to 2015.Romiplostim therapy received 45 patients(group 1) and eltrombopag therapy-15 patients(group 2).Efficacy was evaluated by levels of platelet response and the percentage of patients who managed to cancel or reduce the dose of drugs for concomitant ITP therapy.The main indicators of safety were incidence of adverse events,including thrombotic complications,bleeding and abnormalities in laboratory parameters.
Results
Twenty-one patients (47%) from 1 group and four (28%) from group 2 received two or more lines ITP therapy, nine of them underwent splenectomy .Platelet response was achieved in 88 % patients treated with romiplostim and in 93 % eltrombopag. During aTPO-r therapy the majority of patients (92 % from group 1 and 100% group 2) were able to completely cancel the previous long-term steroid therapy. Resistant to aTPO-r therapy were 8 patients-5(11%) from romiplostim group and 1(7%) eltrombopag group),three of them were splenectomised in future. The most frequent adverse events in romiplostim group were headache,arthralgia and dermatitis. This events were minimal and not require change in therapy.In eltrombopag group noted shot-term hepatotoxicity with the need for correction or therapy(dose reduction or treatment interruption)without additional hepatotropic therapy. Cancel aTpo-r therapy was required in connection with the development of thrombotic complications: 4% patients romiplostim group and 6% eltrombopag. Five patients (4 from the romiplostim group and 1 from eltrombopag) maintained a stable remission after discontinuation of aTPO-r therapy without any treatment.
Conclusion
Presented results confirm high efficiency,favorable safety profile aTPO-r,importance of this drugs in the modern ITP therapy algorithms,which was reflected in the inclusion of aTPO-r in national treatment standarts of ITP therapy.
Session topic: E-poster
Type: Publication Only
Background
Therapy of thrombopoietin receptor agonists( aTPO-r) is a new approach to the treatment of patients with resistant primary ITP.Data on the effectiveness and safety of aTPO-r outside of controlled clinical trials is limited.
Aims
To study the efficacy and safety of prolonged use of aTPO-r in routine clinical practice in patients with chronic ITP in case of loss or inadequate response to at least one line of therapy. To evaluate the possibility of achieving a sustained response after the cessation of the aTPO-r therapy.
Methods
A retrospective analysis of aTPO-r threatment results in chronic ITP patients in the outpatient department in the period from 2010 to 2015.Romiplostim therapy received 45 patients(group 1) and eltrombopag therapy-15 patients(group 2).Efficacy was evaluated by levels of platelet response and the percentage of patients who managed to cancel or reduce the dose of drugs for concomitant ITP therapy.The main indicators of safety were incidence of adverse events,including thrombotic complications,bleeding and abnormalities in laboratory parameters.
Results
Twenty-one patients (47%) from 1 group and four (28%) from group 2 received two or more lines ITP therapy, nine of them underwent splenectomy .Platelet response was achieved in 88 % patients treated with romiplostim and in 93 % eltrombopag. During aTPO-r therapy the majority of patients (92 % from group 1 and 100% group 2) were able to completely cancel the previous long-term steroid therapy. Resistant to aTPO-r therapy were 8 patients-5(11%) from romiplostim group and 1(7%) eltrombopag group),three of them were splenectomised in future. The most frequent adverse events in romiplostim group were headache,arthralgia and dermatitis. This events were minimal and not require change in therapy.In eltrombopag group noted shot-term hepatotoxicity with the need for correction or therapy(dose reduction or treatment interruption)without additional hepatotropic therapy. Cancel aTpo-r therapy was required in connection with the development of thrombotic complications: 4% patients romiplostim group and 6% eltrombopag. Five patients (4 from the romiplostim group and 1 from eltrombopag) maintained a stable remission after discontinuation of aTPO-r therapy without any treatment.
Conclusion
Presented results confirm high efficiency,favorable safety profile aTPO-r,importance of this drugs in the modern ITP therapy algorithms,which was reflected in the inclusion of aTPO-r in national treatment standarts of ITP therapy.
Session topic: E-poster
{{ help_message }}
{{filter}}